Read on Twitter
I am honored to be part of this piece of the lung cancer story. Tepotinib in NSCLC with MET exon 14 skipping mutations. #NSCLC #METex14 #Tepotinib #LCSM https://www.nejm.org/doi/full/10.1056/NEJMoa2004407?source=nejmtwitter&medium=organic-social">https://www.nejm.org/doi/full/...
Of course, there is an incredible team and a ton of work involved in such a publication. Let me tell you about them...
First publications about MET exon 14 skipping date from 2005. Patrick Ma: Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer https://cancerres.aacrjournals.org/content/6...
and Monica Kong-Beltran in 2006 founded the basis. Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer https://cancerres.aacrjournals.org/content/66/1/283.long">https://cancerres.aacrjournals.org/content/6...
In 2015, Paul Paik reported responses to MET inhibitors in 4 NSCLC patients with MET exon 14, confirming the clinical promise. https://cancerdiscovery.aacrjournals.org/content/5/8/842.long">https://cancerdiscovery.aacrjournals.org/content/5...
Then we joined the MET train. Under the clairvoyant
guidance of Rafel Rosell we started to test MET exon 14 in our patients
guidance of Rafel Rosell we started to test MET exon 14 in our patients
Miguel Ángel Molina, head of our lab, fine-tuned the RT-PCR assay and we started the screening
In 2016 Cristina Aguado published our first NSCL patient with MET ex 14 detected in platelet-derived RNA obtained from peripheral blood. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099519/pdf/tlcr-05-05-525.pdf">https://www.ncbi.nlm.nih.gov/pmc/artic...
We were then treating those patients with crizotinib under compassionate use
Then we were selected for clinical trials testing different MET inhibitors: S49076, SYM015 and finally Tepotinib
On the VISION trial we have been able to do molecular screening in more than 250 NSCLC patients. We enrolled 8 patients, and 2 more positive patients have been treated with Tepotinib under compassionate use.
Nowadays we use N-Counter and NGS to detect MET exon 14 skipping alterations and we are refining the liquid biopsy techniques. It is still a great challenge!
So many people contributed to this endeavor... I would like to thank all of them: patients, researchers, the clinical trial unit, the administrative crew. You made this possible!
Some of this amazing people are onTwitter: @almartinezbueno @ccg_galvez @GimnezAna @Doc_FBruno @mgocao @mayoccc @oncorosell @JGarciaMosquera
